NASDAQ:FREQ Frequency Therapeutics (FREQ) Stock Forecast, Price & News $0.39 +0.02 (+5.95%) (As of 09:54 AM ET) Add Compare Share Share Today's Range$0.37▼$0.4150-Day Range$0.36▼$0.7352-Week Range$0.33▼$5.59Volume22,556 shsAverage Volume906,619 shsMarket Capitalization$14.32 millionP/E RatioN/ADividend YieldN/APrice Target$6.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Frequency Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside1,568.4% Upside$6.33 Price TargetShort InterestHealthy1.54% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.07Based on 7 Articles This WeekInsider TradingSelling Shares$36,103 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.70) to ($1.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 starsMedical Sector468th out of 969 stocksPharmaceutical Preparations Industry213th out of 454 stocks 3.0 Analyst's Opinion Consensus RatingFrequency Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.33, Frequency Therapeutics has a forecasted upside of 1,568.4% from its current price of $0.38.Amount of Analyst CoverageFrequency Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.54% of the float of Frequency Therapeutics has been sold short.Short Interest Ratio / Days to CoverFrequency Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Frequency Therapeutics has recently decreased by 3.54%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldFrequency Therapeutics does not currently pay a dividend.Dividend GrowthFrequency Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FREQ. Previous Next 1.6 News and Social Media Coverage News SentimentFrequency Therapeutics has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Frequency Therapeutics this week, compared to 1 article on an average week.Search Interest12 people have searched for FREQ on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Frequency Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Frequency Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,103.00 in company stock.Percentage Held by Insiders16.80% of the stock of Frequency Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.18% of the stock of Frequency Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Frequency Therapeutics are expected to grow in the coming year, from ($1.70) to ($1.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Frequency Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Frequency Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFrequency Therapeutics has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Frequency Therapeutics (NASDAQ:FREQ) StockFrequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.Read More FREQ Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FREQ Stock News HeadlinesSeptember 28, 2023 | businesswire.comBetter Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 DiabetesSeptember 27, 2023 | msn.comBaird Downgrades Frequency Therapeutics (FREQ)October 2, 2023 | PressReach (Ad)Nuclear Revival Creates Opportunities for UraniumUranium companies set to benefit from increased demand for clean energy.September 27, 2023 | americanbankingnews.comFrequency Therapeutics (NASDAQ:FREQ) Stock Rating Lowered by Robert W. BairdSeptember 26, 2023 | markets.businessinsider.comHold Rating on Frequency Therapeutics Amidst Pending Merger and Financing DevelopmentsSeptember 25, 2023 | benzinga.comZucara Therapeutics Doses First Patient in Phase 2a 'ZONE' TrialSeptember 24, 2023 | yahoo.comIf you have recurring nightmares, therapy can help you prevent and rewrite them to get a good night's sleepAugust 18, 2023 | thestreet.comFrequency Therapeutics Inc.October 2, 2023 | PressReach (Ad)Nuclear Revival Creates Opportunities for UraniumUranium companies set to benefit from increased demand for clean energy.August 10, 2023 | finance.yahoo.comFrequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial ResultsJuly 28, 2023 | fool.comFrequency Therapeutics (NASDAQ: FREQ)July 17, 2023 | msn.comFrequency (FREQ) Up 77% on Merger Deal With Korro BioJuly 14, 2023 | benzinga.comFREQ Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Frequency Therapeutics, Inc. Is Fair to ShareholdersJuly 14, 2023 | msn.comKorro Bio absorbs Frequency Therapeutics in reverse biotech mergerJuly 14, 2023 | finance.yahoo.comWhy Are Frequency Therapeutics Shares Surging TodayJuly 14, 2023 | markets.businessinsider.comKorro Bio, Frequency Therapeutics Sign All-stock Merger DealJuly 14, 2023 | seekingalpha.comFrequency Therapeutics jumps on all-stock merger with Korro BioJuly 14, 2023 | marketwatch.comFrequency Therapeutics Shares Soar Premarket on Reverse Merger Deal >FREQJuly 14, 2023 | finance.yahoo.comKorro Bio and Frequency Therapeutics Announce Merger AgreementJuly 14, 2023 | finance.yahoo.comKorro Bio and Frequency Therapeutics Announce Merger AgreementJuly 14, 2023 | investorplace.comWhy Is Frequency Therapeutics (FREQ) Stock Up 44% Today?July 6, 2023 | msn.comBest home radio frequency device for skin tighteningJune 21, 2023 | finance.yahoo.comFREQ - Frequency Therapeutics, Inc.June 7, 2023 | msn.comFrequency Therapeutics to reduce workforce by ~55%May 12, 2023 | msn.comFrequency Therapeutics: Q1 Earnings InsightsMay 12, 2023 | msn.comFrequency Therapeutics GAAP EPS of -$0.55 misses by $0.11May 12, 2023 | finance.yahoo.comFrequency Therapeutics Provides Business Updates and First Quarter 2023 Financial ResultsSee More Headlines Receive FREQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Frequency Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FREQ Company Calendar Last Earnings8/10/2023Today10/02/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FREQ CUSIPN/A CIK1703647 Webwww.frequencytx.com Phone781-315-4600FaxN/AEmployees46Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.33 High Stock Price Forecast$8.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+1,611.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-107.67% Return on Assets-61.40% Debt Debt-to-Equity RatioN/A Current Ratio5.81 Quick Ratio5.81 Sales & Book Value Annual Sales$14.07 million Price / Sales0.96 Cash FlowN/A Price / Cash FlowN/A Book Value$1.96 per share Price / Book0.19Miscellaneous Outstanding Shares36,520,000Free Float30,385,000Market Cap$13.51 million OptionableNot Optionable Beta0.77 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. David L. Lucchino (Age 53)Co-Founder, Pres, CEO & Director Comp: $1.02MMr. Richard J. Mitrano (Age 52)VP of Fin. & Operations Mr. James P. AbelyAssociate Gen. Counsel & Sec.Dr. John L. LaMattina Ph.D. (Age 73)Sr. Advisor & Member of PCA Regenerative Medicine Advisory Board Key CompetitorsVBI VaccinesNASDAQ:VBIVTonix PharmaceuticalsNASDAQ:TNXPRenovoRxNASDAQ:RNXTNabriva TherapeuticsNASDAQ:NBRVCalciMedicaNASDAQ:CALCView All CompetitorsInsiders & InstitutionsDavid L LucchinoSold 2,865 sharesTotal: $1,719.00 ($0.60/share)Richard J MitranoSold 227 sharesTotal: $143.01 ($0.63/share)David L LucchinoSold 2,895 sharesTotal: $1,881.75 ($0.65/share)GTS Securities LLCBought 223,278 shares on 8/16/2023Ownership: 0.611%Richard J MitranoSold 234 sharesTotal: $156.78 ($0.67/share)View All Insider TransactionsView All Institutional Transactions FREQ Stock - Frequently Asked Questions Should I buy or sell Frequency Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Frequency Therapeutics in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FREQ shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FREQ, but not buy additional shares or sell existing shares. View FREQ analyst ratings or view top-rated stocks. What is Frequency Therapeutics' stock price forecast for 2023? 5 brokers have issued 12 month target prices for Frequency Therapeutics' stock. Their FREQ share price forecasts range from $4.00 to $8.00. On average, they anticipate the company's stock price to reach $6.33 in the next year. This suggests a possible upside of 1,611.7% from the stock's current price. View analysts price targets for FREQ or view top-rated stocks among Wall Street analysts. How have FREQ shares performed in 2023? Frequency Therapeutics' stock was trading at $3.85 at the beginning of the year. Since then, FREQ stock has decreased by 90.4% and is now trading at $0.37. View the best growth stocks for 2023 here. When is Frequency Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our FREQ earnings forecast. How were Frequency Therapeutics' earnings last quarter? Frequency Therapeutics, Inc. (NASDAQ:FREQ) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.14. What other stocks do shareholders of Frequency Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Frequency Therapeutics investors own include AbbVie (ABBV), Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Pfizer (PFE), Taiwan Semiconductor Manufacturing (TSM), Atreca (BCEL), Cidara Therapeutics (CDTX), Clovis Oncology (CLVS) and Chimerix (CMRX). When did Frequency Therapeutics IPO? (FREQ) raised $102 million in an initial public offering on Thursday, October 3rd 2019. The company issued 6,700,000 shares at a price of $14.50-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Mizuho Securities was co-manager. What is Frequency Therapeutics' stock symbol? Frequency Therapeutics trades on the NASDAQ under the ticker symbol "FREQ." How do I buy shares of Frequency Therapeutics? Shares of FREQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Frequency Therapeutics' stock price today? One share of FREQ stock can currently be purchased for approximately $0.37. How much money does Frequency Therapeutics make? Frequency Therapeutics (NASDAQ:FREQ) has a market capitalization of $13.51 million and generates $14.07 million in revenue each year. The company earns $-81,580,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. How can I contact Frequency Therapeutics? Frequency Therapeutics' mailing address is 19 PRESIDENTIAL WAY SUITE 203, WOBURN MA, 01801. The official website for the company is www.frequencytx.com. The company can be reached via phone at 781-315-4600 or via email at investorrelations@frequencytx.com. This page (NASDAQ:FREQ) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Frequency Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.